Multi-modality imaging with SPECTRALIS® is helping drive the development of novel therapeutics and changing the course of patient management in eye care. Using an upgradeable platform approach, SPECTRALIS has enhanced the role of spectral-domain OCT by integrating it with confocal scanning laser ophthalmoscopy (cSLO).
The combination of these two technologies has enabled new imaging capabilities, such as TruTrackTM Active Eye Tracking, and BluePeakTM blue laser autofluorescence, providing clinicians with unique views of the structure and function of the eye.

SPECTRALIS patient examination SPECTRALIS device

Patient examination with SPECTRALIS


TruTrack active eye tracking creates a detailed retinal map each time a patient is imaged. The AutoRescanTM feature uses this map to automatically place follow-up scans in precisely the same location as the baseline scan. Once a scan is marked for followup, the AutoRescan tool will find the desired location, eliminating subjective operator placement and increasing clinician ability to observe true change over time rather than change resulting from alignment error. AutoRescan precision has been documented in studies showing that the SPECTRALIS system offers 1 micron measurement reproducibility.


Blood vessel alignment across all visits demonstrates precise rescan placement

BluePeak - Blue Laser Autofluorescence

Without the need for dye, non-invasive BluePeakTM - Blue Laser Autofluorescence imaging takes advantage of the natural fluorescent properties of lipofuscin. BluePeak autofluorescence captures fundus autofluorescence (FAF) images, providing both structural and metabolic information about the retina.

Lipofuscin is a key component of RPE metabolism. Abnormal accumulation of lipofuscin is associated with a number of retinal diseases. Characteristic autofluorescence patterns seen in BluePeak images can reveal the extent of geographic atrophy (GA). It can also assist clinicians in determining the diagnosis and management of hereditary conditions such as Best's disease and Stargardt's disease.

BluePeak - Blue Laser Autofluorescence imaging is a clinical endpoint in studies of emerging therapeutics for geographic atrophy and is becoming an essential tool in the management of degenerative diseases of the retina.


Healthy eye                  Geographic Atrophy                  Retinitis Pigmentosa


The RegionFinderTM software allows for accurate quantification of atrophic areas in BluePeak - Blue Laser Autofluorescence images, the new standard for a non-invasive RPE health check. The unique TruTrack image alignment technology enables precise follow-up measurements including change and trend analysis for reliable disease monitoring.

The RegionFinder has been validated in ongoing studies of emerging therapies for dry AMD. Exclusive analytic capabilities make the RegionFinder an integral part of all SPECTRALIS models with BluePeak designed to provide individualized patient care.

Easy Quantification of Atrophic Areas


Easy quantification of atrophic areas with the RegionFinder software



MultiColorTM - Scanning Laser Imaging brings a new dimension to non-invasive multi-modality fundus imaging with the SPECTRALIS product family.

Simultaneous imaging with multiple laser colors selectively captures and portraits diagnostic information originating from different retinal structures within a single examination. SPECTRALIS MultiColor imaging delivers high contrast, detailed images even in difficult patients including those with cataracts or nystagmus. This is based on the core technologies of confocal scanning laser ophthalmoscopy (cSLO), TruTrack active live eye tracking and Heidelberg Noise ReductionTM technology.

SPECTRALIS combines MultiColor and SD-OCT in a single device creating a new diagnostic platform for simultaneous fundus and cross sectional imaging.


Multiple small to mid-size drusen appear well delineated in the MultiColor image.
The simultaneous SD-OCT image confirms the confluent drusen pattern.

Posterior Pole Asymmetry Analysis

Glaucomatous damage is often marked by retinal thinning in the zone surrounding the fovea and extending toward the optic nerve head. The SPECTRALIS Posterior Pole Asymmetry Analysis maps retinal thickness across the posterior pole and graphs asymmetry both between hemispheres and between eyes reflecting ganglion cell loss. Used with RNFL measurements, the Posterior Pole Asymmetry Analysis can provide a robust picture of glaucoma.

SPECTRALIS Posterior Pole SPECTRALIS Posterior Pole SPECTRALIS Posterior Pole

Posterior Pole Asymmetry Analysis with SPECTRALIS